Janux Therapeutics (JANX) Retained Earnings (2021 - 2026)
Janux Therapeutics' (JANX) quarterly Retained Earnings came in at -$375.7 million in Q1 2026, down 43.8% year-on-year from -$668.5 million in Q1 2025, and down 6.92% on a QoQ basis from -$351.4 million in Q4 2025.
Janux Therapeutics (JANX) Retained Earnings (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 6 years of Retained Earnings data on file, last reported at -$375.7 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 43.8% year-over-year to -$375.7 million in Q1 2026; TTM through Mar 2026 was -$375.7 million, a 43.8% decrease from a year earlier, with the FY2025 full-year figure at -$351.4 million, down 16345.12% from the prior year.
- Retained Earnings for Q1 2026 stood at -$375.7 million, down from -$351.4 million in the prior quarter.
- Over the last five years, Retained Earnings for JANX reached as high as $3.7 million in Q2 2025 and fell as low as -$375.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$147.5 million across 5 years, with a median of -$127.9 million in 2023.
- On a YoY basis, Retained Earnings climbed as much as 101.98% in 2025 and fell as far as 49759.73% in 2025.
- Year by year, Retained Earnings stood at -$110.5 million in 2022, then plunged by 52.77% to -$168.8 million in 2023, then jumped by 101.28% to $2.2 million in 2024, then plunged by 16345.12% to -$351.4 million in 2025, then declined by 6.92% to -$375.7 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$375.7 million in Q1 2026, -$351.4 million in Q4 2025, and -$319.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Janux Therapeutics | 985.11 Mn | 985.11 Mn | - | -375.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -375.70 Mn |
| Dec 31, 2025 | -351.38 Mn |
| Sep 30, 2025 | -319.40 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | -261.27 Mn |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | -217.50 Mn |
| Jun 30, 2024 | -189.50 Mn |
| Mar 31, 2024 | -524,000.00 |
| Dec 31, 2023 | -168.76 Mn |
| Sep 30, 2023 | -157.00 Mn |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -127.93 Mn |
| Dec 31, 2022 | -110.47 Mn |
| Sep 30, 2022 | -94.41 Mn |
| Jun 30, 2022 | -77.70 Mn |
| Mar 31, 2022 | -60.82 Mn |
| Dec 31, 2021 | -270,000.00 |
| Sep 30, 2021 | -34.00 Mn |
| Jun 30, 2021 | -23.23 Mn |